Busulfan liposomal (Calliditas Therapeutics)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameBusulfan liposomal (Calliditas Therapeutics)
Drug Alias NameBusulipoMZH-2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA cross linking agentsDNA synthesis inhibitorsImmunosuppressants
TargetsDNA
Therapy Area/IndicationsBone marrow transplant rejection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKarolinska Institutet
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCalliditas Therapeutics Ab
Active IndicationsN/A
Inactive IndicationsBone marrow transplant rejection

Other Information

ATC CodeN/A
Related LinksN/A